Changes in serum-β2-microglobulin (β2-m) levels were measured in 52 patients with chronic lymphocytic leukaemia during periods of observation of 5–43 months. While the majority of patients had elevated levels ( > 3 mg/l), higher values tended to be associated with more advanced disease as assessed clinically. Patients with nonprogressive, predominantly Rai stage 0 and I disease had persistently normal or near normal β2-m levels, whereas patients with progressive, predominantly Rai stage II-IV disease, had higher levels often showing rapid changes. Sequential measurements of serum β2-m show patterns of change that reflect and may anticipate the clinical progression of the disease.

Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.